These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15116053)

  • 21. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
    García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
    Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
    Verde Z; Santiago C; Valle B; Fernández-Santander A; Bandrés F; Calvo E; Ruiz JR; Lucía A; Gallego FG
    Thromb Haemost; 2009 Mar; 101(3):591-3. PubMed ID: 19277427
    [No Abstract]   [Full Text] [Related]  

  • 24. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.
    Verde Z; Ruiz JR; Santiago C; Valle B; Bandrés F; Calvo E; Lucía A; Gómez Gallego F
    PLoS One; 2010 Jun; 5(6):e11210. PubMed ID: 20585445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.
    D'Ambrosio RL; D'Andrea G; Cappucci F; Chetta M; Di Perna P; Brancaccio V; Grandone E; Margaglione M
    Haematologica; 2004 Dec; 89(12):1510-6. PubMed ID: 15590403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
    Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
    Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A genome-wide association study of acenocoumarol maintenance dosage.
    Teichert M; Eijgelsheim M; Rivadeneira F; Uitterlinden AG; van Schaik RH; Hofman A; De Smet PA; van Gelder T; Visser LE; Stricker BH
    Hum Mol Genet; 2009 Oct; 18(19):3758-68. PubMed ID: 19578179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
    Yildirim H; Tamer L; Sucu N; Atik U
    Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response.
    Nastasi-Catanese JA; Padilla-Gutiérrez JR; Valle Y; Ortega-Gutiérrez F; Gallegos-Arreola MP; Figuera LE
    Genet Mol Res; 2013 Oct; 12(4):4413-21. PubMed ID: 24222221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
    Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
    Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
    Schwarz UI; Stein CM
    Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
    [No Abstract]   [Full Text] [Related]  

  • 35. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
    De T; Christopher R; Nagaraja D
    Thromb Res; 2014 May; 133(5):729-35. PubMed ID: 24530212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Vliet M; van Schaik RH; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Pharmacogenetics; 2004 Jan; 14(1):27-33. PubMed ID: 15128048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism.
    López-Parra AM; Borobia AM; Baeza C; Arroyo-Pardo E; Carcas AJ
    Clin Biochem; 2013 Jan; 46(1-2):167-9. PubMed ID: 22917719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
    Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
    Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.